Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
asparlas | Biologic Licensing Application | 2024-10-08 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
precursor cell lymphoblastic leukemia-lymphoma | — | D054198 | C91.0 |
Expiration | Code | ||
---|---|---|---|
calaspargase pegol, Asparlas, Servier Pharmaceuticals LLC | |||
2101-02-01 | Orphan excl. |
Code | Description |
---|---|
J9118 | Injection, calaspargase pegol-mknl, 10 units |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 13 | 8 | — | 2 | 23 |
Leukemia | D007938 | — | C95 | 3 | 6 | 2 | — | 1 | 10 |
Biphenotypic leukemia acute | D015456 | — | C95.0 | 2 | 3 | 3 | — | — | 8 |
Lymphoma | D008223 | — | C85.9 | 1 | 6 | 2 | — | — | 7 |
Lymphoid leukemia | D007945 | — | C91 | — | 6 | 2 | — | — | 6 |
Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | — | 4 | 3 | — | — | 6 |
Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | — | 2 | 3 | — | — | 5 |
Burkitt lymphoma | D002051 | — | C83.7 | — | 1 | 2 | — | — | 3 |
Central nervous system neoplasms | D016543 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 4 | — | — | — | 4 |
Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 1 | — | — | — | 4 |
T-cell lymphoma | D016399 | — | — | 1 | 1 | — | — | — | 2 |
Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
T-cell lymphoma peripheral | D016411 | — | — | 1 | — | — | — | — | 1 |
T-cell leukemia | D015458 | — | — | 1 | — | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Drug common name | Calaspargase pegol |
INN | calaspargase pegol |
Description | Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged one month to 21 years.
|
Classification | Enzyme |
Drug class | enzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 941577-06-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2108728 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB14730 |
UNII ID | T9FVH03HMZ (ChemIDplus, GSRS) |